On Monday, Merge Healthcare Inc. (NASDAQ:MRGE)’s shares declined -0.28% to $7.08.
Merge Healthcare Incorporated (MRGE), a leading provider of health information systems for medical imaging, interoperability, and communication, declared its financial and business results for the second quarter of 2015.
Financial Summary:
- GAAP net sales raised 22% to $65.6 million in the second quarter of 2015 contrast to $53.8 million in the second quarter of 2014;
- GAAP net income in the second quarter of 2015 was $2.0 million (or $0.01 per share) contrast to a loss of $4.0 million (or ($0.04) per share) in the second quarter of 2014 (which comprised of a $4.8 million debt refinancing charge);
- Adjusted net income raised 132% to $10.2 million (or $0.09 per share) in the second quarter of 2015 contrast to $4.4 million (or $0.05 per share) in the second quarter of 2014;
- Adjusted EBITDA was $16.7 million (or 25% of GAAP net sales) in the second quarter of 2015 contrast to $11.2 million (or 21% of GAAP net sales) in the second quarter of 2014; and
- Cash balances reduced to $20.6 million as of June 30, 2015, contrast to $23.9 million as of June 30, 2014, a decrease of 14%, primarily as a result of about $20 million of cash expended in 2015 to acquire D.R. Systems, Inc.
Merge Healthcare Incorporated develops software solutions that facilitate the sharing of images to create an electronic healthcare experience for patients and physicians worldwide. It operates in two segments, Merge Healthcare and Merge DNA. The company provides iConnect Enterprise Archive and iConnect Access Enterprise Viewer, an interoperability and connectivity platform for imaging and diagnostic data access; iConnect Network to electronically manage in-bound medical imaging referrals and distribution of results to referring physicians; iConnect Cloud Archive, a cloud-based and multi-tenant image archive that provides disaster recovery/business continuity services; and iConnect Retinal Screening, a software solution for the screening of chronic visual diseases.
Total System Services, Inc. (NYSE:TSS)’s shares dropped -5.01% to $43.38.
TSYS® (TSS) and Acquirer Systems declared the launch of ASTREX, a new testing solution that simplifies the EMV® certification process for both Value-Added Resellers (VARs) and Integrated Software Vendors (ISVs). Developers can now use a streamlined approach to integrate with TSYS’ current testing environment, where ASTREX provides a robust card brand simulation tool with real-time results. The efficient testing functionality cuts EMV certification time in half.
As an EMV payments simulation platform, developers can test a full range of transactions and network scenarios. This powerful and comprehensive testing solution eliminates complex integration steps with its scalability, and also reduces overall EMV implementation costs. ASTREX gives VARs and ISVs the peace of mind that their POS solutions will qualify for EMV certification on the first attempt.
Total System Services, Inc. provides electronic payment processing services to banks and other financial institutions in the United States, Europe, Canada, Mexico, and internationally. It operates through four segments: North America Services, International Services, Merchant Services, and NetSpend. The company offers account processing and output services, counting processing the card application, initiating service for the cardholder, processing card transaction for the issuing retailer or financial institution, and accumulating the account’s transactions.
At the end of Monday’s trade, Air Products & Chemicals, Inc. (NYSE:APD)‘s shares dipped -3.72% to $132.37.
Air Products (APD), a global leader in helium production, recently held a grand opening at its new Doe Canyon helium production facility in Colorado. The Doe Canyon helium plant is the only one in the world extracting helium from a gas stream composed primarily of carbon dioxide (CO2). The helium from this new facility further diversifies Air Products’ supply chain to ensure a reliable and stable supply of product for its customers.
Much of the helium produced in the United States recently comes from the United States Bureau of Land Administration (BLM) system, however, the BLM system is in decline, and eventually that storage supply will be depleted. At the same time, the world’s demand for helium is likely to continue to grow and is why new sources of helium are needed. The purified helium at the new Colorado facility will be liquefied on-site for subsequent delivery to Air Products’ customers. The plant is predictable to produce up to 230 million standard cubic feet of helium per year, replacing more than 15 percent of the current BLM reserve helium supply as that system declines.
Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, performance materials, equipment, and services worldwide. The company operates in Merchant Gases, Tonnage Gases, Electronics and Performance Materials, and Equipment and Energy segments. The Merchant Gases segment sells atmospheric gases, such as oxygen, nitrogen, and argon; process gases, such as hydrogen, helium, and carbon dioxide; specialty gases; temporary gas supply services; and equipment for the metals, glass, electronics, chemical processing, food processing, healthcare, general manufacturing, and petroleum and natural gas industries.
WuXi PharmaTech (Cayman) Inc. (ADR) (NYSE:WX), ended its Monday’s trading session with -4.85% loss, and closed at $40.97.
WuXi PharmaTech (Cayman) Inc. (WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries with operations in China and the United States, recently declared that it has reached a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New WuXi Life Science Limited (“Parent”) and WuXi Merger Limited (“Merger Sub”), a wholly owned partner of Parent.
Following the Merger Agreement, Parent will acquire the Company for cash consideration equal to US$5.75 per ordinary share of the Company (each, a “Share”) and US$46 per American Depositary Share of the Company, each representing eight Shares (each, an “ADS”), or about US$3.3 billion in aggregate cash consideration. This represents a 16.5% premium over the closing price of US$39.50 per ADS as quoted by the New York Stock Exchange (the “NYSE”) on April 29, 2015, and a premium of 18.9% and 20.1%, respectively, over the Company’s 30- and 60- trading day volume-weighted average price as quoted by the NYSE preceding to April 29, 2015, the last trading day preceding to the Company’s declarement on April 30, 2015 that it had received a non-binding “going private” proposal.
Wuxi PharmaTech (Cayman) Inc. operates as a pharmaceutical, biotechnology, and medical device research and development services company in China and the United States. It operates through two segments, Laboratory Services and Manufacturing Services. The Laboratory Services segment offers services for small molecules, such as synthetic chemistry, biology, medicinal chemistry, DMPK/ADME, formulation, analytical chemistry, toxicology, clinical development, bioanalytical, genomics, bioinformatics, research reagent production, and clinical services; services for discovery and development of biologics; and laboratory services, counting testing services for biologics, medical devices, and combination products, in addition to production of cell therapies.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
